[l] 陈万青,邹小农,张思维.中国肝癌死亡率地理分布分析[J].实用肿瘤学杂志,2008,22(3):201-203.
[2] 叶家才,崔书中,巴明臣.原发性肝癌的流行病学特征及其危险因素[J].实用医学杂志,2008,24(10):1839.
[3] 钦伦秀,孙惠川,汤钊散.原发性肝癌研究进展[J].中华外科杂志,2006,44:1070.
[4] Hübner M, McCormack L, Clavien PA. Surgical therapy of liver tumors: resection vs. ablation [J]. Praxis, 2005, 94:1255-1259.
[5] Lencioni R,de Baere T,Burrel M,et al.Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead(DEBDOX):technical recommendations[J]. Cardiovasc Intervent Radiol,2012,35( 5) :980-985.
[6] LivraghiT,Goldberg SN,Lazzaroni S, et al. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions[J].Radiology, 2000,214:761-768.
[7] Llovet JM,Di Bisceglie AM,Bruix J,et al. Design and endpoints of clinical trials in hepatocellular carcinoma[J].J Natl Cancer Inst.2008.100:698-711.
[8] Kume A,Nimura Y,Kamiya J,et al. Percutaneous ethanol injection via an artificially induced right hydrothorax for hepatocellular carcinoma in the hepatic dome[J]. Cardiovasc Intervent Radiol,2003,26( 6) : 543-549.
[9] 李力军,于世平,孙兴臣,等.放射性粒子组织间永久植入治疗晚期胰腺癌[J].中华外科杂志,2003,41( 9) : 717.
[10] 黄文才,沈钧康,钱铭辉,等.肝脏急性放射性损伤超顺磁性氧化铁增强 MRI 实验研究[J]. 中华放射学杂志, 2007, 41(01): 95-97.
[11] Popescu CC,Wise J,Sowards K,et a1.Dosimetric characteristics of the Pharma Seed model BT-125-I source[J]. Med Phys, 2000, 27(5):2174-2181.
[12] 贺克武,高斌.CT导引下125I粒子组织间植入治疗肿瘤的新进展[J].临床放射学杂志,2007,26:926-928.
[13] 付吕平, 郭志远, 刘卫红,等. TACE 联合放射性125I 粒子瘤内植入治疗肝癌 [J]. 标记免疫分析与临床,2013,20:207-209 |